FAP
Fibroblast activation protein
Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.
All Product Categories
-
FAP Related Products (84)
Related Products (84)
-
Antibodies (4)
-
NOTA-SP2A-FAPT
0 ImagesCat. No.: HY-P11599NOTA-SP2A-FAPT is a fibroblast activation protein (FAP) ligand. NOTA-SP2A-FAPT can be adiolabeled and exhibits rapid renal excretion with fast kidney tissue clearance, accumulates rapidly in and retains high levels in FAP-positive tumor xenografts to enable clear tumor visualization. NOTA-SP2A-FAPT can be used as a tracer of cancer.
-
Cys-FAP targeting peptide for FXX489
0 ImagesCat. No.: HY-P10945ACys-FAP targeting peptide for FXX489 is a FAP-targeting peptide for FXX489 (HY-P10945) that incorporates a Cys (cysteine) residue. It can undergo conjugation reactions via the thiol group of the cysteine residue.
-
DOTA-C1-FAP-2286
0 ImagesCat. No.: HY-P11602CAS No.: 3107530-08-2DOTA-C1-FAP-2286 is a cysteic acid-modified fibroblast activation protein (FAP)-targeting radioligand. DOTA-C1-FAP-2286 binds competitively to FAP with an IC50 of 127.64 nM. DOTA-C1-FAP-2286 is targeted accumulation in FAP-expressing cells and exhibits accelerated renal clearance. DOTA-C1-FAP-2286 can be used as a PET/CT tracer in cancer.
-
FAPI-P8PN
0 ImagesCat. No.: HY-175322CAS No.: 2921619-09-0FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.
-
Faridoxorubicin
0 ImagesCat. No.: HY-177083CAS No.: 1841402-73-0Synonyms: AVA-6000Faridoxorubicin (AVA-6000) is a FAP-activated chemotherapeutic prodrug. Faridoxorubicin undergoes selective hydrolysis by FAP, while it is resistant to cleavage by related mammalian peptidases and members of the DASH subfamily. Faridoxorubicin acts as a tumor growth inhibitor, reducing tumor volume and prolonging survival in in vivo models and PDX models with high FAP expression. Faridoxorubicin can be used in the research of osteosarcoma and sarcoma.
-
Fluorogen binding modulator-1
0 ImagesCat. No.: HY-148361CAS No.: 510716-65-1Fluorogen binding modulator-1 (PubChem SID 125240934) is a fluorogen activating protein (FAP)-fluorogen binding modulator with -log EC50s of 6.61 and 6.37 for AM2.2-β2AR and AM2.2-GPR32, respectively.
-
FAP-IN-7
0 ImagesCat. No.: HY-175685CAS No.: 3020777-28-7FAP-IN-7 (Compound 5b) is a FAP-
FAP6-19
0 ImagesCat. No.: HY-159771CAS No.: 3095069-75-0FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
-
BR103354
0 ImagesCat. No.: HY-182250CAS No.: 2505339-87-5BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.
-
DOTA-NI-FAPI-04
0 ImagesCat. No.: HY-170779CAS No.: 3078291-78-5DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact.
-
FSDD3I
0 ImagesCat. No.: HY-146182CAS No.: 3035764-23-6FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
-
OncoFAP-EN-DOTAGA
0 ImagesCat. No.: HY-176958CAS No.: 2639365-74-3OncoFAP-EN-DOTAGA is a FAP (fibroblast activation protein) targeting conjugate compound. OncoFAP-EN-DOTAGA can chelate radioactive isotopes (such as ) Ga-68 or fluorescent agent and can be used as a probe with targeting binding functions.
-
Zilganersen
0 ImagesCat. No.: HY-P3392CAS No.: 2305355-56-8Synonyms: ION373Zilganersen (ION373) is a gapmer antisense oligonucleotide targeting glial fibrillary acidic protein (GFAP). Zilganersen reduces excess glial fibrillary acidic protein produced by disease-causing variants in the GFAP gene and inhibits synthesis of GFAP. Zilganersen can be used for the research of Alexander disease.
-
I-FAPI-04 prodrug-1
0 ImagesCat. No.: HY-186190CAS No.: 3032403-10-1
-
UAMC-1110 (Standard)
0 ImagesCat. No.: HY-100684RCAS No.: 1448440-52-5UAMC-1110 (Standard) is the analytical standard of UAMC-1110 (HY-100684). This product is intended for research and analytical applications. UAMC-1110 is a highly potent and selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 3.2 nM. UAMC-1110 also inhibits prolyl oligopeptidase (PREP) with an IC50 of 1.8 μM.
